Company intelligence / Profile preview
1910 Genetics
Boston, Massachusetts, United States1910genetics.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
1910 Genetics has developed a proprietary multimodal AI-driven drug discovery platform integrating computational data and laboratory automation. The company has launched CANDID-CNS™, an AI model for predicting blood-brain barrier permeability that outperforms industry standards. No clinical-stage results have been reported yet; the pipeline is in preclinical development[5][6].
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Small moleculesLarge molecules (including protein therapeutics)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Microsoft (five-year commercial agreement for R&D productivity with AI tools)[2]Accenture Ventures/Accenture[8]
Beyond the preview
Go deeper on 1910 Genetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1910 Genetics.